XTL Biopharmaceuticals (XTLB) updates on Social Proxy leadership exits

Rhea-AI Filing Summary

XTL Biopharmaceuticals Ltd. reports that Tal Klinger, Chief Executive Officer of its wholly owned Israeli subsidiary Social Proxy Ltd., and Roee Klinger, the subsidiary’s Chief Technology Officer, have resigned from their positions effective immediately as of December 11, 2025. The company states that it is evaluating next steps for the management of Social Proxy Ltd. and plans to provide further updates when appropriate.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of December 2025

Commission File Number: 001-36000 

XTL Biopharmaceuticals Ltd.

(Translation of registrant’s name into English)

26 Ben-Gurion St.

Ramat Gan,
5112001, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

XTL Biopharmaceuticals Ltd. (the “Company”) announces that on December 11, 2025, Tal Klinger, Chief Executive Officer of Social Proxy Ltd., an Israeli company and wholly owned subsidiary of the Company, and Roee Klinger, Chief Technology Officer of Social Proxy Ltd., submitted a letter of resignation from their respective positions, effective immediately.

The Company is evaluating next steps with respect to the management of Social Proxy Ltd. and will provide updates as appropriate.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	XTL BIOPHARMACEUTICALS LTD.
Date: December 12, 2025	By:	/s/ Noam Band
		Noam Band
		Chief Executive Officer

2

FAQ

What did XTL Biopharmaceuticals Ltd. (XTLB) disclose in this update?

XTL Biopharmaceuticals Ltd. disclosed that the Chief Executive Officer and Chief Technology Officer of its wholly owned subsidiary Social Proxy Ltd. have resigned effective immediately.

Which executives resigned from Social Proxy Ltd., the XTLB subsidiary?

Tal Klinger, Chief Executive Officer of Social Proxy Ltd., and Roee Klinger, Chief Technology Officer of Social Proxy Ltd., submitted letters of resignation from their respective positions.

When did the Social Proxy Ltd. resignations take effect?

The resignations of Tal Klinger and Roee Klinger from Social Proxy Ltd. were stated to be effective immediately on December 11, 2025.

What is the relationship between Social Proxy Ltd. and XTL Biopharmaceuticals Ltd. (XTLB)?

Social Proxy Ltd. is an Israeli company and a wholly owned subsidiary of XTL Biopharmaceuticals Ltd.

How is XTL Biopharmaceuticals Ltd. responding to the leadership changes at Social Proxy Ltd.?

The company states that it is evaluating next steps regarding the management of Social Proxy Ltd. and will provide updates as appropriate.

Does this 6-K mention any financial data for XTL Biopharmaceuticals Ltd. (XTLB)?

No financial data is mentioned; the disclosure focuses on the immediate resignations of key executives at the subsidiary Social Proxy Ltd.